Microfluidic Tumor-on-Chip Platform for Metastasis Testing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating advanced and metastatic cancers, such as colon and breast cancer, are limited by late diagnosis and poor response to chemotherapy, particularly in elderly patients, highlighting the need for better compounds and methods to inhibit cancer invasion and metastasis.
Innovation Solution
A microfluidic platform or 'chip' system that simulates tumor invasion by growing tumor cells with non-cancerous tissues, allowing interaction with immune cells to inhibit metastatic activity, and testing immunomodulatory agents, providing insights into cancer angiogenesis and immune surveillance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chemotherapy is used to treat metastatic cancer, then tumor growth may be inhibited, but treatment effectiveness is poor particularly in elderly patients
Solution Approach 1:
The patent introduces microfluidic devices as intermediary platforms that simulate the human tumor microenvironment, allowing immunotherapeutics to be tested in a physiologically relevant system before clinical application. This intermediary testing system bridges the gap between in vitro studies and in vivo human responses, enabling better prediction of treatment effectiveness in elderly patients without exposing them to ineffective chemotherapies.
Solution Approach 2:
The patent employs preliminary testing of immunotherapeutics using microfluidic tumor models before clinical deployment. By conducting preclinical evaluations in realistic microenvironmental conditions, the system identifies effective treatments in advance, allowing for personalized treatment selection that anticipates patient response patterns, particularly in elderly populations who may have reduced chemotherapy tolerance.
2Reliability
If cancer is diagnosed at advanced stage, then treatment options are limited, but early detection methods are insufficient
Solution Approach 1:
The patent creates simplified copies of human tumors using microfluidic devices that replicate key microenvironmental features. These tumor-on-chip models serve as surrogates for human cancer, enabling researchers to study tumor progression and test therapies in advance. This copying approach accelerates the identification of effective treatments that can be applied earlier in the clinical setting, potentially improving early detection and intervention strategies.
3Loss of information
If microfluidic platforms are used to test immunotherapeutics, then understanding of cancer invasion is enhanced, but device complexity increases
Solution Approach 1:
The patent divides the complex task of studying cancer metastasis into segmented functional modules within microfluidic devices. The system separates tumor cell culture, immune cell interaction, and microenvironmental gradient generation into distinct but integrated components. This segmentation allows each module to be optimized independently while maintaining overall system functionality, making the complex device more manageable and easier to manufacture.
Solution Approach 2:
The patent designs microfluidic platforms with universal features that can accommodate multiple experimental configurations. The devices incorporate standardized interfaces, reusable components, and adaptable chamber designs that allow the same basic platform to test various immunotherapeutics and tumor types. This multi-functionality reduces overall device complexity by eliminating the need for entirely separate systems for different applications.
Data Source
AI summary
The invention generally relates to a microfluidic platforms or “chips” for testing and understanding cancer, and, more specifically, for understanding the factors that contribute to cancer invading tissues and causing metastases. Tumor cells are grown on microfluidic devices with other non-cancerous tissues under conditions that simulate tumor invasion. The interaction with immune cells can be tested to inhibit this activity by linking a cancer chip to a lymph chip.